36 citations,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
35 citations,
October 2017 in “JAMA dermatology” Children with alopecia areata should only have thyroid screening if they have Down syndrome, a history of atopy, family history of thyroid disease, or signs of thyroid problems.
31 citations,
March 2017 in “Journal of The American Academy of Dermatology” Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.
30 citations,
June 2017 in “Journal of cutaneous medicine and surgery” Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
24 citations,
December 2010 in “Dermatologic surgery” Botulinum toxin type A injections are not effective for severe alopecia areata.
22 citations,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
22 citations,
January 2017 in “Acta Endocrinologica” A woman with multiple autoimmune diseases showed improvement in hair loss but not in skin discoloration after treatment.
21 citations,
April 2019 in “Journal of cutaneous pathology” People with alopecia areata have fewer regulatory T-cells than those with other skin conditions.
20 citations,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
19 citations,
July 2019 in “Journal of Cosmetic Dermatology” A new tool can predict hair regrowth in patchy alopecia areata patients.